• The MIMETiv research project, which will focus on the active substances TOTUM•070 and TOTUM•448 developed by Valbiotis, will be carried out by a joint laboratory, partly funded by the National Research Agency (ANR) to the tune of 363,000 €.
• This work will make it possible to develop, by 2024, the most complete model of the human upper digestive tract in the world, integrating in particular the microbiota of the small intestine.
• The expected results will support the non-drug strategies against metabolic and cardiovascular diseases developed by Valbiotis, in particular the herbal active substances TOTUM•070 and TOTUM•448.
• The MIMETiv project will provide exclusive data on the metabolites, bioavailability, mode of action at the intestinal level and effects on the human microbiota of these two active substances.